Ascentage Pharma Group International’s (AAPG) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a report released on Thursday morning,Benzinga reports. BTIG Research currently has a $48.00 target price on the stock.

A number of other research analysts have also issued reports on the stock. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Oppenheimer began coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target for the company. Finally, Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target for the company. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and a consensus price target of $48.00.

Ascentage Pharma Group International Stock Performance

AAPG opened at $22.96 on Thursday. The stock has a fifty day moving average of $24.01 and a 200-day moving average of $29.79. Ascentage Pharma Group International has a fifty-two week low of $17.56 and a fifty-two week high of $48.45. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million for the quarter.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of large investors have recently bought and sold shares of the company. Tema Etfs LLC bought a new position in Ascentage Pharma Group International in the 2nd quarter valued at about $610,000. XY Capital Ltd boosted its position in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares in the last quarter. UBS Group AG boosted its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the third quarter valued at approximately $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.